Achilles therapeutics to present early proof of concept of safety and clinical activity of clonal neoantigen reactive t cells at the esmo immuno-oncology annual congress 2022

- durable partial response (pr) and stable disease (sd) achieved in heavily pre-treated non-small cell lung cancer (nsclc) patients dosed with cnet monotherapy -

ACHL Ratings Summary

ACHL Quant Ranking